Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Whither Type 1 Diabetes?

Literature DB >> 33207099

Whither Type 1 Diabetes?

Domenico Accili¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2020 PMID： 33207099 PMCID： PMC8996297 DOI： 10.1056/NEJMe2030472

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

8 in total

1. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.

Authors: Elizabeth J Mayer-Davis; Jean M Lawrence; Dana Dabelea; Jasmin Divers; Scott Isom; Lawrence Dolan; Giuseppina Imperatore; Barbara Linder; Santica Marcovina; David J Pettitt; Catherine Pihoker; Sharon Saydah; Lynne Wagenknecht
Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245

Review 2. Changing the landscape for type 1 diabetes: the first step to prevention.

Authors: Colin M Dayan; Maria Korah; Danijela Tatovic; Brian N Bundy; Kevan C Herold
Journal: Lancet Date: 2019-09-15 Impact factor: 79.321

3. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Authors: Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum
Journal: N Engl J Med Date: 2019-06-09 Impact factor: 91.245

4. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors: Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112

5. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.

Authors: Teresa Quattrin; Michael J Haller; Andrea K Steck; Eric I Felner; Yinglei Li; Yichuan Xia; Jocelyn H Leu; Ramineh Zoka; Joseph A Hedrick; Mark R Rigby; Frank Vercruysse
Journal: N Engl J Med Date: 2020-11-19 Impact factor: 91.245

Review 6. New Frontiers in the Treatment of Type 1 Diabetes.

Authors: Jeremy T Warshauer; Jeffrey A Bluestone; Mark S Anderson
Journal: Cell Metab Date: 2019-12-12 Impact factor: 27.287

7. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.

Authors: Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Matthias Hebrok; Kevan C Herold; Domenico Accili; Massimo Pietropaolo; Peter R Arvan; Matthias Von Herrath; Dorene S Markel; Christopher J Rhodes
Journal: Diabetes Date: 2011-05 Impact factor: 9.461

8. Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.

Authors: Laura M Jacobsen; Brian N Bundy; Madison N Greco; Desmond A Schatz; Mark A Atkinson; Todd M Brusko; Clayton E Mathews; Kevan C Herold; Stephen E Gitelman; Jeffrey P Krischer; Michael J Haller
Journal: Diabetes Technol Ther Date: 2020-10-20 Impact factor: 6.118

8 in total

4 in total

Whither Type 1 Diabetes?

1. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.

Review 2. Changing the landscape for type 1 diabetes: the first step to prevention.

3. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

4. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

5. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.

Review 6. New Frontiers in the Treatment of Type 1 Diabetes.

7. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.

8. Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.

Review 1. Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.

Review 2. Type 1 diabetes mellitus: much progress, many opportunities.

Review 3. Diabetes type 1: Can it be treated as an autoimmune disorder?

Review 4. Functional Role of miR-155 in the Pathogenesis of Diabetes Mellitus and Its Complications.